Blue Cross Laboratories Private Limited

Blue Cross Laboratories Private Limited, established on July 9, 1980, is a prominent Indian pharmaceutical company headquartered in Mumbai, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U24230MH1980PTC022825. With an authorized capital of ₹100 crore and a paid-up capital of ₹64.8 crore, Blue Cross Laboratories has demonstrated consistent growth and financial stability.

Over the years, the company has expanded its operations, offering a diverse range of pharmaceutical products across various therapeutic segments. Its commitment to quality and affordability has earned it a significant presence in both domestic and international markets. The company's portfolio includes leading brands such as "MEFTAL" and "TUSQ," which are trusted names in India and abroad.

Blue Cross Laboratories operates WHO-GMP-certified manufacturing facilities located in Nasik and Goa, India. These facilities are equipped to produce a wide array of pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's manufacturing capabilities are designed to meet both domestic and international standards, ensuring the delivery of high-quality products to its global clientele.

The leadership team at Blue Cross Laboratories is headed by Managing Director Bhalchandra Barve Govind, who has been with the company since May 18, 1998. Other key executives include Whole-Time Director Ashish Mangesh Shirsat, appointed on September 1, 2006, and Director Rajendra Yeshwant Padhye, who joined on November 17, 2010. The company's leadership is further strengthened by the presence of directors such as Rohit Jayaramdas Patel and Ketki Raj Wadhawa, appointed on December 5, 2007, and April 15, 2020, respectively.

Blue Cross Laboratories has established a strong presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities in Nasik and Goa are WHO-GMP-certified, enabling them to produce pharmaceutical formulations that meet international regulatory standards. This certification facilitates the company's ability to export products to these markets, ensuring compliance with stringent quality and safety requirements.

The company has made significant inroads into emerging markets across Africa, Latin America, and Southeast Asia. By obtaining WHO-GMP certification for its manufacturing facilities, Blue Cross Laboratories has enhanced its ability to access these markets, where there is a growing demand for affordable and high-quality pharmaceutical products. The company's expansion into these regions underscores its commitment to improving global healthcare access.

Blue Cross Laboratories has strategically diversified its geographic footprint to mitigate concentration risks. By expanding into both regulated and emerging markets, the company has balanced its portfolio, reducing dependency on any single region. This approach not only spreads risk but also positions the company to capitalize on growth opportunities in various global markets.

As of March 2026, specific details regarding Blue Cross Laboratories' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's WHO-GMP certification indicates adherence to international manufacturing standards, which is a prerequisite for exporting to regulated markets like the United States. However, for detailed FDA-related information, direct consultation with the FDA's databases or the company's official communications is recommended.

Blue Cross Laboratories' manufacturing facilities in Nasik and Goa are certified by the World Health Organization's Good Manufacturing Practices (WHO-GMP). This certification attests to the company's commitment to maintaining high-quality manufacturing standards. While the company has WHO-GMP certification, specific details regarding EU GMP certificates or EDQM status are not publicly disclosed. For comprehensive information, it is advisable to consult the company's official communications or relevant regulatory bodies.

Blue Cross Laboratories holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. These licenses authorize the company to produce pharmaceutical formulations for both domestic and international markets. The company's adherence to CDSCO regulations ensures compliance with national standards for drug manufacturing and distribution.

As of March 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Blue Cross Laboratories by regulatory authorities such as the FDA. The company's WHO-GMP certification and compliance with CDSCO regulations suggest a strong commitment to maintaining high manufacturing standards. For the most current and detailed information, it is recommended to consult the FDA's official databases or the company's official communications.

In the pharmaceutical industry, Blue Cross Laboratories faces competition from both domestic and international companies operating in similar therapeutic segments. While specific market share data is not publicly disclosed, the company's leading brands, "MEFTAL" and "TUSQ," are recognized and trusted names in India and abroad. The company's WHO-GMP-certified manufacturing facilities and diverse product portfolio position it competitively in the market.

Blue Cross Laboratories distinguishes itself through its commitment to quality, affordability, and a diverse product portfolio. The company's WHO-GMP-certified manufacturing facilities in Nasik and Goa enable it to produce a wide range of pharmaceutical formulations that meet international standards. Brands like "MEFTAL" and "TUSQ" exemplify the company's focus on delivering trusted healthcare solutions to a global audience.

Blue Cross Laboratories continues to focus on expanding its presence in both regulated and emerging markets. The company's strategic direction emphasizes maintaining high manufacturing standards, as evidenced by its WHO-GMP certification, and offering a diverse range of pharmaceutical products to meet global healthcare needs. Looking ahead, the company is well-positioned to leverage its strengths in quality manufacturing and brand recognition to achieve sustained growth and success.

Blue Cross Laboratories has demonstrated a consistent track record in pharmaceutical manufacturing, with a diverse product portfolio and a commitment to quality. The company's WHO-GMP-certified facilities in Nasik and Goa reflect its dedication to maintaining high manufacturing standards. While specific export volumes and consistency metrics are not publicly disclosed, the company's established presence in both domestic and international markets indicates reliability and trustworthiness as a supplier.

Importers should verify the following certifications when considering Blue Cross Laboratories as a supplier:

• WHO-GMP Certification: Confirms adherence to international manufacturing standards. Verification can be done through the company's official communications or by contacting the World Health Organization.

• CDSCO Manufacturing License: Indicates compliance with Indian national standards for drug manufacturing. Verification can be conducted through the Central Drugs Standard Control Organisation's official channels.

• FDA Facility Registration: If exporting to the United States, ensure the manufacturing facility is registered with the FDA. Verification can be done through the FDA's official database.

• EU GMP Certificate: For exports to the European Union, verify the EU GMP certification. This can be done through the company's official communications or relevant EU regulatory bodies.

When conducting due diligence on Blue Cross Laboratories, consider the following steps:

• Verify Certifications: Confirm WHO-GMP, CDSCO, FDA, and EU GMP certifications as applicable.

• Review Regulatory Compliance: Check for any recent regulatory actions, such as warning letters or import alerts.

• Assess Financial Stability: Review the company's financial statements for indicators of financial health.

• Evaluate Product Portfolio: Analyze the diversity and quality of the product range.

• Conduct Site Visits: If possible, visit manufacturing facilities to assess compliance with quality standards.

• Check References: Obtain feedback from existing clients or partners regarding their experiences with the company.

By following this checklist, importers can ensure a comprehensive evaluation of Blue Cross Laboratories as a potential supplier.